May 5,BeiGeneDisclose the company’s first quarter of 2022performanceReport. In the first quarter, the company’s revenue was $306.6 million, compared to $605.9 million in the same period in 2021. Total product revenue was $261.6 million, compared to $106.1 million for the same period in 2021.
ććBeiGeneis a global biotechnology company focused on the development and commercialization of innovative drugs.
During the reporting period,BeiGeneProduct revenue reached a new high, totaling US$261.6 million, an increase of 146% compared to US$106.1 million in the same period last year, mainly due to the increase in sales of self-developed products and licensed products. The company said that the core self-developed BTK inhibitor Baiyueze has achieved strong performance, and the global growth trend has accelerated significantly. In the first quarter, Baiyueze’s global sales were US$104.3 million, a year-on-year increase of 372%. In the U.S., Baiyue Zeās sales were $67.9 million, up 570% year-over-year. In China, Baiyue Ze’s sales were $33.5 million, up 180% year-over-year. In addition, as the pioneer and leader of local innovative drugs going overseas, the company is continuing to expand the global commercialization of Baiyueze. At present, Baiyueze has been approved for multiple indications in 47 countries and regions around the world. Commercialized listings in multiple markets.
The self-developed anti-PD-1 antibody Bai Zean maintained a stable growth trend. In the first quarter, Bai Zean’s sales in China were US$87.6 million, a year-on-year increase of 79%. At present, Baizean has been approved for 8 indications in China, of which 5 indications have been included in the national medical insurance catalogue, which is the PD-1 mAb with the largest number of indications included in the medical insurance catalogue. At the same time, through cooperation with Novartis, a number of marketing applications of Baizean have been accepted by the US FDA and the European Medicines Agency, and are currently under review, and are expected to achieve their first overseas launch within this year.
ććBeiGeneChief Financial Officer Ms. Wang Aijun said, “In the first quarter, we witnessed significant revenue growth in the company’s commercial product portfolio, especially self-developed products, in all regions. With the continuous approval of listing applications and the expected milestones. , we expect the company’s revenue to continue to maintain good momentum in the future. At the same time, with the company’s strong financial position, we will also further strengthen the financial position and look forward to the next many expected milestones.”
Global strategic cooperation provides support for subsequent growth.the first quarter, byAmgenSales of the company’s licensed products in China doubled compared to the same period last year, totaling $29.9 million;Bristol-Myers SquibbThe company’s authorized sales of products sold in China amounted to US$27.2 million, a year-on-year increase of 34%. During the reporting period,BeiGeneThe authorization and introduction of 5 Novartis anti-tumor products that have been approved and covered by medical insurance have been completed, and they have begun to be promoted in the Chinese market.
It is reported that the company vigorously promotes the global clinical layout and progress of the follow-up pipeline products. Among them, the TIGIT inhibitor ospelimumab, which is in the late clinical stage, has launched two global clinical phase III trials and five clinical phase II trials. More than 1000 subjects were enrolled in more than 25 countries and regions. The company plans to initiate additional pivotal clinical trials for osperimab and the BCL-2 inhibitor BGB-11417 this year, and continue to advance the clinical progress of other early-stage pipeline products and collaborative drug candidates.
Continue to invest in R&D and production to accelerate the further expansion and diversification of the global supply chain. The new production base and clinical research and development center in New Jersey, USA has officially broken ground, and the initial construction is expected to start in 2022; the new small molecule innovative drug industrialization base in Suzhou has started construction, and it is expected to have the highest production capacity of small molecule drugs in China Increase to 10 times the current level; the new phase of construction of the Guangzhou biopharmaceutical production base is expected to be completed by the end of 2022 and meet GMP standards, and the total production capacity will reach 64,000 liters by then.
ććBeiGeneJohn V. Oyler, Co-Founder, Chairman and Chief Executive Officer, said, “The company made tremendous progress in the first quarter, continuing to strengthen the company with its global commercialization performance in Asia, the U.S. and Europe. strategic competitive advantage, including the groundbreaking of a flagship manufacturing facility and clinical R&D center in the Princeton West Innovation Campus in Hopewell, NJ, USA. Baiyue Ze and Bai ZeAmgenA further testament to our strengths in advancing global clinical development, delivering impactful treatment options for cancer patients, and more. BeiGene Announces Long-Term Follow-Up Results from the Global Phase 3 ‘Head-to-Head’ Trial of the ALPINE Study; Independent Review Committee Evaluation of Baiyueze Demonstrates Superiority over Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia The overall remission rate was consistently lower in Nepal, and the incidence of atrial fibrillation or flutter was consistently low. In addition, with the positive results of the global trial RATIONALE306 for the first-line treatment of advanced esophageal cancer, the company’s cooperation with Novartis also made new progress in the Baizean program. BeiGene has established a dominant position and will further promote the development of product pipelines and the expansion of its global layout to meet the needs of patients around the world. “
(Article source: ShanghaisecuritiesNewspaper Chinasecuritiesnetwork)